The drug Wegovy uses an active ingredient called Semaglutide which is part of a growing class of GLP-1 drugs that make people ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
Those taking the drugs for at least three years cut their risk of heart attack, stroke or cardiac death by 20 per cent ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount ...
A weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three ...
Research suggests that these drugs may reduce the risk of heart attack, stroke, and other cardiovascular issues even for ...
Marketed as Wegovy, Ozempic and Rybelsus, semaglutide injections may benefit obese patients even if they don't lose weight.
Ozempic could dramatically reduce the risk of heart attacks and stroke, a new study indicates. The weight loss jab has become ...
The five-year study explored if the drug sold under the brand names Wegovy, Ozempic and Rybelsus could reduce the risk of ...
A study has found the anti-obesity drug sold under brand names Wegovy, Ozempic and Rybelsus could reduce the risk of heart attacks, strokes ...